KALA BIO Inc. Common Stock (KALA)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I keep looking for businesses that earn real money and sell at a sensible price. KALA BIO does not yet meet that test. It describes itself as developing an on-premises AI infrastructure platform for biotechnology research, with just six employees, and filed figures show no revenue in fiscal Q2 2026, the quarter ended 2026-06-30. Losses are narrowing: net income was -$42.2 million in FY2023, -$38.5 million in FY2024, and -$27.0 million in FY2025, and the fiscal Q2 2026 net loss was -$1.6 million. Still, trailing free cash flow is -$19.9 million, a -13.0% FCF yield on a $152.5 million market cap. At the 2026-10-13 close of $0.26, FairStock calculates a P/B of 0.55 and a P/E of -0.02. A price below book can look attractive, but a Piotroski F-Score of 0/9 and an Altman Z-Score of -31.83 signal financial distress. The company's Lynch category is none because it lost money in each of the last four years. I see no durable competitive moat: the AI platform is unproven, the KPI-012 dataset is described as a proof-of-concept environment, and there is no revenue history. The narrowing losses are encouraging, but they may reflect cost cuts rather than a viable business. The 52-week range of $0.10 to $5.90 and a beta of -2.41 suggest speculation, not a stable moat. Without commercial validation, cash runway, and revenue, the low price is not a margin of safety; it is a bet on an early-stage pivot.

In plain English: KALA BIO is a small healthcare company trying to build AI tools for biotechnology research. It reports no sales and has been losing money, though the losses have become smaller recently. The stock price is very low compared with the value of its assets on paper, but without sales and with cash still going out, the business looks weak and the price is hard to call truly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer